New drug combo shows promise for rare, Hard-to-Treat cancers
NCT ID NCT05142241
First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 26 times
Summary
This study tests whether a combination of two drugs, talazoparib and temozolomide, can shrink advanced rare cancers or stop them from growing. The trial includes 14 adults with rare solid tumors that have not responded to standard treatments. Talazoparib blocks a protein that helps cancer cells repair their DNA, while temozolomide damages cancer cell DNA directly, aiming to kill the cells together.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALIGNANT SOLID NEOPLASM are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Cancer Institute Developmental Therapeutics Clinic
Bethesda, Maryland, 20892, United States
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
Conditions
Explore the condition pages connected to this study.